BeOne Medicines Ltd - American Depositary Shares — Bilan (NASDAQ:ONC)

Afficher le graphique complet Full chart

Financials

Total de l'actif 5.6 B8.65 B6.38 B5.81 B5.92 B8.19 B Total du passif 1.73 B2.4 B2 B2.27 B2.59 B3.83 B Total des capitaux propres 3.87 B6.24 B4.38 B3.54 B3.33 B4.36 B Total du passif et des capitaux propres 5.6 B8.65 B6.38 B5.81 B5.92 B8.19 B Dette totale 183.64 M202.11 M209.15 M197.62 M166.48 M1.03 B Dette nette 183.64 M202.11 M209.15 M197.62 M166.48 M-3.59 B

BeOne Medicines Ltd - American Depositary Shares

BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market. BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025.